Symbols / APGE Stock $132.55 +46.66% Apogee Therapeutics, Inc.
APGE (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteApogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Ratings
Current target
$132.55
Low
$81.00
High
$160.00
Mean
$119.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-06-22 | down | Canaccord Genuity | Buy → Hold | $135 |
| 2026-06-08 | main | RBC Capital | Sector Perform → Sector Perform | $97 |
| 2026-05-27 | main | Truist Securities | Hold → Hold | $81 |
| 2026-05-27 | reit | BTIG | Buy → Buy | $137 |
| 2026-05-27 | main | Wedbush | Outperform → Outperform | $135 |
| 2026-05-01 | init | Rothschild & Co | — → Buy | $140 |
| 2026-03-30 | main | Mizuho | Outperform → Outperform | $110 |
| 2026-03-24 | main | Citigroup | Buy → Buy | $125 |
| 2026-03-24 | main | Canaccord Genuity | Buy → Buy | $130 |
| 2026-03-24 | main | Guggenheim | Buy → Buy | $160 |
| 2026-03-23 | reit | BTIG | Buy → Buy | $137 |
| 2026-03-18 | init | Truist Securities | — → Hold | $83 |
| 2026-03-16 | reit | BTIG | Buy → Buy | $137 |
| 2026-03-03 | main | RBC Capital | Sector Perform → Sector Perform | $82 |
| 2026-03-03 | main | Wedbush | Outperform → Outperform | $95 |
| 2026-01-22 | down | RBC Capital | Outperform → Sector Perform | $83 |
| 2026-01-07 | init | Wolfe Research | — → Peer Perform | — |
| 2026-01-06 | main | BTIG | Buy → Buy | $137 |
| 2026-01-05 | main | BTIG | Buy → Buy | $128 |
| 2025-12-17 | init | Stephens & Co. | — → Overweight | $95 |
- AbbVie’s $10.9 Billion Apogee Therapeutics Buyout Protects Its Immunology Crown - Barron's Mon, 22 Jun 2026 12
- APGE Stock Surges On Trial Win And $1.3B Blackstone Deal - StocksToTrade Mon, 22 Jun 2026 18
- AbbVie pays $10.9B for Apogee to expand immunology pipeline - Stock Titan Mon, 22 Jun 2026 11
- Stocks making the biggest moves premarket: Apogee Therapeutics, SpaceX, Arcosa & more - CNBC Mon, 22 Jun 2026 11
- AbbVie: Why The Pharma Wins Twice With Its Apogee Acquisition (NASDAQ:APGE) - Seeking Alpha Mon, 22 Jun 2026 19
- APGE Stock Jumps As Blackstone Deal Backs Breakout Trial Data - timothysykes.com Mon, 22 Jun 2026 19
- Apogee Therapeutics (NASDAQ:APGE) stock jumps on AbbVie’s $10.9 billion cash takeover - TechStock² Mon, 22 Jun 2026 14
- APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - marketscreener.com Mon, 22 Jun 2026 13
- 3 Stocks To Watch Today: APGE, MLTX, ORKA - RTTNews Mon, 22 Jun 2026 12
- AbbVie (ABBV) to Acquire Apogee Therapeutics (APGE) for $10.9 Bi - GuruFocus Mon, 22 Jun 2026 14
- APGE Stock Surges As Street Backs Zumilokibart Breakout - StocksToTrade Mon, 22 Jun 2026 20
- APGE (NASDAQ: APGE) files Form 144 listing recent 10b5-1 sales - Stock Titan Mon, 22 Jun 2026 20
- APGE Stock Rallies As Street Backs Zumilokibart Breakthrough - timothysykes.com Mon, 22 Jun 2026 13
- Apogee: "Hold" On AbbVie $10.9B Buyout And Extended Half-Life IL-13 Zumilokibart For AD - Seeking Alpha Mon, 22 Jun 2026 19
- APGE Stock Climbs As Street Backs Zumilokibart Momentum - StocksToTrade Mon, 22 Jun 2026 16
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
285.60
+31.69%
|
216.87
+133.19%
|
93.00
+202.68%
|
30.73
|
| Research And Development |
|
214.71
+27.91%
|
167.87
+145.33%
|
68.42
+146.25%
|
27.79
|
| Selling General And Administration |
|
69.75
+42.34%
|
49.01
+99.38%
|
24.58
+735.74%
|
2.94
|
| General And Administrative Expense |
|
69.75
+42.34%
|
49.01
+99.38%
|
24.58
+735.74%
|
2.94
|
| Salaries And Wages |
|
50.64
+67.10%
|
30.30
+140.94%
|
12.58
+665.96%
|
1.64
|
| Other Gand A |
|
19.12
+2.22%
|
18.70
-23.91%
|
24.58
+1792.15%
|
1.30
|
| Total Expenses |
|
285.60
+31.69%
|
216.87
+133.19%
|
93.00
+202.68%
|
30.73
|
| Operating Income |
|
-285.60
-31.69%
|
-216.87
-133.19%
|
-93.00
-202.68%
|
-30.73
|
| Total Operating Income As Reported |
|
-285.60
-31.69%
|
-216.87
-133.19%
|
-93.00
-202.68%
|
-30.73
|
| EBITDA |
|
-284.18
-31.15%
|
-216.68
-132.98%
|
-93.00
-203.58%
|
-30.64
|
| Normalized EBITDA |
|
-284.18
-31.15%
|
-216.68
-132.98%
|
-93.00
-203.58%
|
-30.64
|
| Reconciled Depreciation |
|
1.42
+650.26%
|
0.19
|
0.00
|
—
|
| EBIT |
|
-285.60
-31.69%
|
-216.87
-133.19%
|
-93.00
-203.58%
|
-30.64
|
| Net Income |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Pretax Income |
|
-255.56
-40.32%
|
-182.13
-116.86%
|
-83.98
-111.10%
|
-39.78
|
| Net Non Operating Interest Income Expense |
|
30.03
-13.56%
|
34.74
+285.25%
|
9.02
+199.56%
|
-9.06
|
| Interest Expense Non Operating |
|
—
|
—
|
0.00
-100.00%
|
9.15
|
| Net Interest Income |
|
30.03
-13.56%
|
34.74
+285.25%
|
9.02
+199.56%
|
-9.06
|
| Interest Expense |
|
—
|
—
|
0.00
-100.00%
|
9.15
|
| Interest Income Non Operating |
|
30.03
-13.56%
|
34.74
+285.25%
|
9.02
+9702.17%
|
0.09
|
| Interest Income |
|
30.03
-13.56%
|
34.74
+285.25%
|
9.02
+9702.17%
|
0.09
|
| Tax Provision |
|
0.28
+1444.44%
|
0.02
|
0.00
|
—
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Net Income From Continuing Operation Net Minority Interest |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Net Income From Continuing And Discontinued Operation |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Net Income Continuous Operations |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Normalized Income |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Net Income Common Stockholders |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Diluted EPS |
|
-3.74
-13.34%
|
-3.30
+1.79%
|
-3.36
-130.11%
|
-1.46
|
| Basic EPS |
|
-3.74
-13.34%
|
-3.30
+1.79%
|
-3.36
-130.11%
|
-1.46
|
| Basic Average Shares |
|
68.40
+23.93%
|
55.19
+120.72%
|
25.01
-8.22%
|
27.25
|
| Diluted Average Shares |
|
68.40
+23.93%
|
55.19
+120.72%
|
25.01
-8.22%
|
27.25
|
| Diluted NI Availto Com Stockholders |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Depreciation Amortization Depletion Income Statement |
|
1.13
|
0.00
|
—
|
—
|
| Depreciation And Amortization In Income Statement |
|
1.13
|
0.00
|
—
|
—
|
| Depreciation Income Statement |
|
1.13
|
0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
937.13
+24.30%
|
753.95
+87.83%
|
401.40
+163.99%
|
152.06
|
| Current Assets |
|
741.36
+39.95%
|
529.71
+32.96%
|
398.41
+162.02%
|
152.06
|
| Cash Cash Equivalents And Short Term Investments |
|
730.19
+40.25%
|
520.65
+31.66%
|
395.46
+160.36%
|
151.89
|
| Cash And Cash Equivalents |
|
131.55
-7.22%
|
141.79
+19.84%
|
118.32
-22.10%
|
151.89
|
| Cash Financial |
|
—
|
—
|
—
|
151.89
|
| Other Short Term Investments |
|
598.64
+58.01%
|
378.86
+36.70%
|
277.14
|
0.00
|
| Receivables |
|
5.96
+26.91%
|
4.70
+286.90%
|
1.21
|
—
|
| Accrued Interest Receivable |
|
5.96
+26.91%
|
4.70
+286.90%
|
1.21
|
—
|
| Prepaid Assets |
|
4.60
+75.51%
|
2.62
+50.98%
|
1.74
+1507.41%
|
0.11
|
| Other Current Assets |
|
0.60
-65.27%
|
1.74
+43.49%
|
1.21
+2029.82%
|
0.06
|
| Total Non Current Assets |
|
195.78
-12.69%
|
224.24
+7387.08%
|
3.00
|
0.00
|
| Net PPE |
|
14.38
+7.89%
|
13.32
+413.65%
|
2.59
|
0.00
|
| Gross PPE |
|
15.98
+18.28%
|
13.51
+420.93%
|
2.59
|
0.00
|
| Accumulated Depreciation |
|
-1.61
-750.79%
|
-0.19
|
0.00
|
—
|
| Properties |
|
0.00
|
0.00
|
0.00
|
—
|
| Machinery Furniture Equipment |
|
2.75
|
0.00
|
—
|
—
|
| Other Properties |
|
10.16
-19.72%
|
12.65
+387.66%
|
2.59
|
—
|
| Leases |
|
3.08
+256.32%
|
0.86
|
0.00
|
—
|
| Investments And Advances |
|
172.73
-17.91%
|
210.42
|
0.00
|
—
|
| Other Non Current Assets |
|
8.67
+1641.16%
|
0.50
+24.19%
|
0.40
|
—
|
| Total Liabilities Net Minority Interest |
|
33.25
-10.51%
|
37.16
+72.90%
|
21.49
+115.34%
|
9.98
|
| Current Liabilities |
|
27.91
-2.29%
|
28.56
+38.92%
|
20.56
+105.99%
|
9.98
|
| Payables And Accrued Expenses |
|
20.74
-11.47%
|
23.43
+21.47%
|
19.29
+103.80%
|
9.46
|
| Payables |
|
1.22
+14.01%
|
1.07
-50.02%
|
2.14
+412.68%
|
0.42
|
| Accounts Payable |
|
1.22
+14.01%
|
1.07
-50.02%
|
2.14
+412.68%
|
0.42
|
| Current Accrued Expenses |
|
19.52
-12.69%
|
22.36
+30.40%
|
17.15
+89.53%
|
9.05
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.66
+93.03%
|
1.90
+1034.73%
|
0.17
-67.57%
|
0.52
|
| Current Debt And Capital Lease Obligation |
|
3.50
+8.35%
|
3.23
+193.73%
|
1.10
|
—
|
| Current Capital Lease Obligation |
|
3.50
+8.35%
|
3.23
+193.73%
|
1.10
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
5.34
-37.83%
|
8.60
+821.44%
|
0.93
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
5.34
-37.83%
|
8.60
+821.44%
|
0.93
|
0.00
|
| Long Term Capital Lease Obligation |
|
5.34
-37.83%
|
8.60
+821.44%
|
0.93
|
0.00
|
| Stockholders Equity |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
|
0.00
|
| Common Stock Equity |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
|
0.00
|
| Capital Stock |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Preferred Stock |
|
—
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
68.40
+15.00%
|
59.48
+22.59%
|
48.52
+1.04%
|
48.02
|
| Ordinary Shares Number |
|
68.40
+15.00%
|
59.48
+22.59%
|
48.52
+1.04%
|
48.02
|
| Additional Paid In Capital |
|
1,464.56
+43.33%
|
1,021.79
+103.00%
|
503.35
|
0.00
|
| Retained Earnings |
|
-561.76
-83.63%
|
-305.92
-147.16%
|
-123.77
-211.10%
|
-39.78
|
| Gains Losses Not Affecting Retained Earnings |
|
1.08
+18.03%
|
0.92
+178.12%
|
0.33
|
0.00
|
| Other Equity Adjustments |
|
1.08
+18.03%
|
0.92
+178.12%
|
0.33
|
—
|
| Total Equity Gross Minority Interest |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
+167.40%
|
142.07
|
| Total Capitalization |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
+167.40%
|
142.07
|
| Working Capital |
|
713.45
+42.36%
|
501.15
+32.63%
|
377.85
+165.95%
|
142.07
|
| Invested Capital |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
|
0.00
|
| Total Debt |
|
8.85
-25.20%
|
11.83
+481.66%
|
2.03
|
0.00
|
| Capital Lease Obligations |
|
8.85
-25.20%
|
11.83
+481.66%
|
2.03
|
0.00
|
| Net Tangible Assets |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
|
0.00
|
| Tangible Book Value |
|
903.88
+26.10%
|
716.79
+88.67%
|
379.91
|
0.00
|
| Available For Sale Securities |
|
172.73
-17.91%
|
210.42
|
—
|
—
|
| General Partnership Capital |
|
—
|
—
|
—
|
2.14
|
| Investmentin Financial Assets |
|
172.73
-17.91%
|
210.42
|
0.00
|
—
|
| Limited Partnership Capital |
|
—
|
0.00
|
0.00
-100.00%
|
181.86
|
| Total Partnership Capital |
|
—
|
-305.00
-147.08%
|
-123.44
-186.88%
|
142.07
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-227.45
-32.88%
|
-171.17
-128.96%
|
-74.76
-355.11%
|
-16.43
|
| Cash Flow From Continuing Operating Activities |
|
-227.45
-32.88%
|
-171.17
-128.96%
|
-74.76
-355.11%
|
-16.43
|
| Net Income From Continuing Operations |
|
-255.84
-40.46%
|
-182.15
-116.88%
|
-83.98
-111.10%
|
-39.78
|
| Depreciation Amortization Depletion |
|
1.42
+650.26%
|
0.19
|
0.00
|
—
|
| Depreciation |
|
1.42
+650.26%
|
0.19
|
0.00
|
—
|
| Depreciation And Amortization |
|
1.42
+650.26%
|
0.19
|
0.00
|
—
|
| Other Non Cash Items |
|
3.68
+117.06%
|
1.69
+1847.13%
|
0.09
-99.24%
|
11.40
|
| Stock Based Compensation |
|
46.28
+98.34%
|
23.33
+282.30%
|
6.10
+184.92%
|
2.14
|
| Change In Working Capital |
|
-15.48
-673.13%
|
-2.00
-132.79%
|
6.11
-37.80%
|
9.81
|
| Change In Prepaid Assets |
|
-2.11
+65.36%
|
-6.08
-118.31%
|
-2.79
-1587.88%
|
-0.17
|
| Change In Payables And Accrued Expense |
|
-0.92
-117.70%
|
5.22
-43.67%
|
9.27
-7.14%
|
9.98
|
| Change In Accrued Expense |
|
-1.07
-117.07%
|
6.29
-17.79%
|
7.65
-19.95%
|
9.56
|
| Change In Payable |
|
0.15
+113.99%
|
-1.07
-166.46%
|
1.61
+285.89%
|
0.42
|
| Change In Account Payable |
|
0.15
+113.99%
|
-1.07
-166.46%
|
1.61
+285.89%
|
0.42
|
| Change In Other Current Assets |
|
-8.47
-8628.87%
|
-0.10
+9.35%
|
-0.11
|
0.00
|
| Change In Other Current Liabilities |
|
-3.98
-280.96%
|
-1.04
-287.04%
|
-0.27
|
0.00
|
| Investing Cash Flow |
|
-179.57
+40.23%
|
-300.46
-9.69%
|
-273.91
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
-179.57
+40.23%
|
-300.46
-9.69%
|
-273.91
|
0.00
|
| Net PPE Purchase And Sale |
|
-5.15
-346.79%
|
-1.15
-589.82%
|
-0.17
|
0.00
|
| Purchase Of PPE |
|
-5.15
-346.79%
|
-1.15
-589.82%
|
-0.17
|
0.00
|
| Capital Expenditure |
|
-5.15
-346.79%
|
-1.15
-589.82%
|
-0.17
|
—
|
| Net Investment Purchase And Sale |
|
-174.43
+41.72%
|
-299.31
-9.34%
|
-273.74
|
0.00
|
| Purchase Of Investment |
|
-642.30
+1.10%
|
-649.45
-113.82%
|
-303.74
|
0.00
|
| Sale Of Investment |
|
467.87
+33.62%
|
350.14
+1067.13%
|
30.00
|
0.00
|
| Financing Cash Flow |
|
396.49
-19.92%
|
495.11
+56.98%
|
315.39
+87.38%
|
168.32
|
| Cash Flow From Continuing Financing Activities |
|
396.49
-19.92%
|
495.11
+56.98%
|
315.39
+87.38%
|
168.32
|
| Net Common Stock Issuance |
|
389.63
-21.04%
|
493.48
+56.47%
|
315.39
|
0.00
|
| Proceeds From Stock Option Exercised |
|
6.86
+321.65%
|
1.63
|
0.00
|
—
|
| Changes In Cash |
|
-10.53
-144.88%
|
23.47
+170.53%
|
-33.28
-121.91%
|
151.89
|
| Beginning Cash Position |
|
142.08
+19.79%
|
118.61
-21.91%
|
151.89
|
0.00
|
| End Cash Position |
|
131.55
-7.41%
|
142.08
+19.79%
|
118.61
-21.91%
|
151.89
|
| Free Cash Flow |
|
-232.60
-34.97%
|
-172.33
-129.99%
|
-74.93
-356.13%
|
-16.43
|
| Amortization Of Securities |
|
-7.50
+38.72%
|
-12.24
-298.60%
|
-3.07
|
0.00
|
| Common Stock Issuance |
|
389.63
-21.04%
|
493.48
+56.47%
|
315.39
|
0.00
|
| Issuance Of Capital Stock |
|
389.63
-21.04%
|
493.48
+56.47%
|
315.39
+87.38%
|
168.32
|
| Net Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
168.32
|
| Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
168.32
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-06-22 View
- 8-K2026-06-22 View
- 42026-06-12 View
- 8-K2026-06-12 View
- 42026-06-11 View
- 42026-06-11 View
- 42026-06-11 View
- 42026-06-11 View
- 42026-06-11 View
- 42026-06-11 View
- 42026-06-05 View
- 8-K2026-05-27 View
- 8-K2026-05-27 View
- 42026-05-15 View
- 10-Q2026-05-11 View
- 8-K2026-05-11 View
- 42026-05-08 View
- 42026-05-04 View
- 8-K2026-04-24 View
- 42026-04-20 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|